First patient receives partial epigenetic reprogramming for glaucoma

In June, a patient in the United States became the first person to receive ER 100, an experimental therapy that uses partial epigenetic reprogramming. The treatment is being tested for age-related optic nerve diseases, including glaucoma, and marks the first human trial of an approach that aims to make aged cells behave more youthfully.

The therapy involves controlled expression of three transcription factors, OCT4, SOX2 and KLF4, to restore youthful patterns of gene expression. The trial is currently limited to specific cells in the eye. Whether the therapy proves safe and effective remains unknown.

The development comes as researchers increasingly focus on healthspan, how long people remain healthy and capable, rather than merely extending lifespan. Cellular rejuvenation has moved from laboratory research into human testing, though the approach remains experimental.